Head of Compliance: GONE ???
- Thread starter anonymous
- Start date
-
- Tags
- None
What’s the story - why did she get fired.
I hope she takes a good look in the mirror.
What took so long ? She was never a good business partner. The only thing she knew was ‘no’.
Something must have happened. Box of rocks from the start, but for her to get canned means ???
Major dysfunction in that one.
No doubt. It’s not often your head of compliance just disappears. Something’s not right.
Oct. 7, 2019 10:30 UTC
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer, reporting to John LaRocca, Aerie’s General Counsel. Ms. Davis will oversee the world wide compliance and data privacy functions for the Company. She most recently held a related position at Sun Pharmaceutical Industries, Inc.
In connection with her acceptance of the position as Vice President and Chief Compliance Officer, Ms. Davis will receive awards totaling 50,060 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date. This award was made outside of Aerie’s stockholder-approved equity incentive plan and was approved by the Company’s independent directors as an inducement material to Ms. Davis entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.
Oct. 7, 2019 10:30 UTC
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer, reporting to John LaRocca, Aerie’s General Counsel. Ms. Davis will oversee the world wide compliance and data privacy functions for the Company. She most recently held a related position at Sun Pharmaceutical Industries, Inc.
In connection with her acceptance of the position as Vice President and Chief Compliance Officer, Ms. Davis will receive awards totaling 50,060 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date. This award was made outside of Aerie’s stockholder-approved equity incentive plan and was approved by the Company’s independent directors as an inducement material to Ms. Davis entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.
She had something on somebody at Sun and got a $$$ package to go away.
#bestmoneyspent